NCT02207920View on ClinicalTrials.gov

Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
HIV Infections
Interventions
BIOLOGICAL

AIDSVAX B/E Vaccine

600 mcg/mL to be administered as 1 mL intramuscular (IM) injection

BIOLOGICAL

DNA-HIV-PT123 Vaccine

4 mg/mL to be administered as 1 mL IM injection

BIOLOGICAL

Placebo for DNA-HIV-PT123

Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection

BIOLOGICAL

Placebo for AIDSVAX B/E

Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection

Trial Locations (7)

10065

New York Blood Center CRS, New York

14642

University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester

19104

Penn Prevention CRS, Philadelphia

94143

Bridge HIV CRS, San Francisco

10032-3732

Columbia P&S CRS, New York

37232-2582

Vanderbilt Vaccine (VV) CRS, Nashville

98109-1024

Seattle Vaccine and Prevention CRS, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02207920 - Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults | Biotech Hunter | Biotech Hunter